150 related articles for article (PubMed ID: 32341397)
1. Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients.
Cai L; Tong Y; Zhu X; Shen K; Zhu J; Chen X
Sci Rep; 2020 Apr; 10(1):7029. PubMed ID: 32341397
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
4. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Sheridan W; Scott T; Caroline S; Yvonne Z; Vanessa B; David V; Karen G; Stephen C
Breast Cancer Res Treat; 2014 Oct; 147(3):617-29. PubMed ID: 25209005
[TBL] [Abstract][Full Text] [Related]
6. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
8. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
9. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer.
Chavez-MacGregor M; Clarke CA; Lichtensztajn DY; Giordano SH
JAMA Oncol; 2016 Mar; 2(3):322-9. PubMed ID: 26659132
[TBL] [Abstract][Full Text] [Related]
10. Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
Pomponio MK; Keele LJ; Fox KR; Clark AS; Matro JM; Shulman LN; Tchou JC
Breast Cancer Res Treat; 2019 Aug; 177(1):137-143. PubMed ID: 31119565
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC
Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
14. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.
Morante Z; Ruiz R; Araujo JM; Pinto JA; Cruz-Ku G; Urrunaga-Pastor D; Namuche F; Flores C; Mantilla R; Luján MG; Fuentes H; Schwarz L; Aguilar A; Neciosup S; Gómez HL
Clin Breast Cancer; 2021 Jun; 21(3):239-246.e4. PubMed ID: 33221201
[TBL] [Abstract][Full Text] [Related]
15. Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
Lohmann AE; Soldera SV; Pimentel I; Ribnikar D; Ennis M; Amir E; Goodwin PJ
J Natl Cancer Inst; 2021 Nov; 113(11):1465-1475. PubMed ID: 33620467
[TBL] [Abstract][Full Text] [Related]
16. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
[TBL] [Abstract][Full Text] [Related]
17. Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer.
Heeg E; Marang-van de Mheen PJ; Van Maaren MC; Schreuder K; Tollenaar RAEM; Siesling S; Bos MEMM; Vrancken Peeters MTFD
Int J Cancer; 2020 Jul; 147(1):152-159. PubMed ID: 31721193
[TBL] [Abstract][Full Text] [Related]
18. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
Chen S; Liu Y; Ouyang QW; Huang L; Luo RC; Shao ZM
Ann Surg Oncol; 2015 Jan; 22(1):32-9. PubMed ID: 25012266
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
